Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Finished Goods (2016 - 2024)

Historic Finished Goods for Astrazeneca (AZNCF) over the last 10 years, with Q4 2024 value amounting to $1.5 billion.

  • Astrazeneca's Finished Goods fell 325.26% to $1.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 billion, marking a year-over-year decrease of 325.26%. This contributed to the annual value of $1.5 billion for FY2024, which is 325.26% down from last year.
  • According to the latest figures from Q4 2024, Astrazeneca's Finished Goods is $1.5 billion, which was down 325.26% from $1.6 billion recorded in Q4 2023.
  • In the past 5 years, Astrazeneca's Finished Goods ranged from a high of $2.0 billion in Q4 2021 and a low of $1.4 billion during Q4 2022
  • For the 5-year period, Astrazeneca's Finished Goods averaged around $1.6 billion, with its median value being $1.5 billion (2024).
  • Its Finished Goods has fluctuated over the past 5 years, first soared by 4060.1% in 2021, then tumbled by 2977.14% in 2022.
  • Quarter analysis of 5 years shows Astrazeneca's Finished Goods stood at $1.4 billion in 2020, then skyrocketed by 40.6% to $2.0 billion in 2021, then fell by 29.77% to $1.4 billion in 2022, then grew by 10.97% to $1.6 billion in 2023, then decreased by 3.25% to $1.5 billion in 2024.
  • Its Finished Goods stands at $1.5 billion for Q4 2024, versus $1.6 billion for Q4 2023 and $1.4 billion for Q4 2022.